Posts by Follicle Thought
Kintor Announces US Phase 2 Trial Results In Male AGA
On May 11, 2023, Kintor Pharmaceutical of China announced results from their US phase 2 trial testing KX-826 aka pyrilutamide in males with androgenetic alopecia. Successful Phase 2 Trial For US KX-826 Trial As is the trend for Kintor Pharmaceutical’s AGA programs, today’s announcement included positive results in a human trial. This milestone will help…
Read MoreCosmeRNA Release Date Update
A new brief update has been shared about the official launch of the anticipated cosmeceutical CosmeRNA from the siRNAgen & Bioneer companies. CosmeRNA is a topical siRNA serum which inhibits the production of the androgen receptor protein using small interfering RNAs. It has been clinically tested in Korea, and Europe through the Dermatest agency and…
Read MoreHair Growth Industry Happenings Spring 2023
As we head into Q2 2023, the hair growth treatment industry continues to develop and make progress in various ways. Kintor Begins Phase 2 Trial For GT20029 Drug This news appeared one day following the publishing of this article. Kintor Pharmaceutical of China has dosed the first patient in a trial which will comprise 180…
Read MoreOral Minoxidil For Hair: Should You Use It?
Oral minoxidil is becoming an increasingly popular treatment option for hair loss patients. This article will discuss a few background points regarding this phenomenon. Low-Dose Oral Minoxidil For Hair Growth Over the past 3-4 years, the prescription and use of oral minoxidil for hair loss has increased. This trend was likely driven by several peer-reviewed…
Read MoreInssen & APstem Therapeutics: New AGA Companies 2023
The pool of biotechs which have expanded their sights into the hair regrowth field continues to grow in 2023. Inssen Multi-Targeted Affipep Technology Inssen is a Korean-based biotech company with Swedish roots, a bit of a rare combination. Its platform technology called “Affipep” combines novel affibody molecules with functional peptides to create selective therapeutics which…
Read MorePelage Pharmaceuticals Unveils Website: Exclusive
The UCLA spinout with a focus on hair follicle stem cells has fully emerged into the public eye. Pelage Pharma PP405 More than six years in the making, Pelage Pharmaceuticals has an official website and an exciting drug candidate on its hands – PP405. Back in 2017, Drs. Bill Lowry and Heather Christofk of the…
Read MoreAlopecia Clinical Trial Forecast For 2023
An overview of treatments for pattern baldness and alopecia which will be in the clinical trial stage during 2023. Androgenetic Alopecia Trials Chong Kun Dang Pharmaceutical – We begin the list with a newcomer, previously unannounced. CKD-843 is a new injectable drug being trialed in “alopecia” by the Chong Kun Dang (CKD) Pharmaceutical company of Seoul,…
Read MoreIntroducing HairDAO: Crowdsourcing A Cure For Hair Loss
A new type of open-source corporation has emerged with an intriguing goal in mind: to leverage the scientific community and hair loss experiencers worldwide to fund and create new treatments for hair loss. New HairDAO Study With Dr. Ralf Paus A recent press release from HairDAO announced their first funded project, which turned out to…
Read MoreKeratin Injectables For Hair Growth: KeraMedix
A new interesting startup aimed at hair growth has emerged, once again, from Korea – KeraMedix. New Study Published By Nature Portfolio On November 19, 2022, the Communications Biology journal of Nature Portfolio published the study “Keratin-mediated hair growth and its underlying biological mechanism” by researchers from Kyung Hee and Konkuk Universities in South Korea. Unbeknownst to…
Read MoreJW Pharmaceutical To Trial Wnt Drug JW0061 For Hair Regrowth In 2024
Korean company JW Pharmaceutical announces that it will participate in the upcoming Wnt 2022 Conference to unveil hair growth related data. JW0061 Pipeline Drug For Hair Loss Since 2017, it’s been known that the Wnt pathway specialists at JW Pharmaceutical had their sights set on hair regeneration. It was announced in the media that the company…
Read More